Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study

KAHALY, G., SCHREZENMEIR, J., KRAUSE, U., SCHWEIKERT, B., MEUER, S., MULLER, W., DENNERAUM, R., BEYER, J.·1986·European Journal of Clinical Investigation

Abstract

Abstract Forty patients with Graves' ophthalmopathy stages III–V were divided into two groups in a random manner according to their year of birth. Group I received prednisone in decreasing dosage. Group II received prednisone at a comparable dosage and ciclosporin. Steroids were discontinued after 10 weeks in the two groups. In the patients of group II, ciclosporin was continued over 12 months. The therapeutic effect was assessed by an activity score based on subjective and objective symptoms (computerized tomography and sonography of the orbit, Hertel values, clinical findings). All signs of endocrine ophthalmopathy improved significantly in both groups (P less than 0·01 in group I; P less than 0·001 in group II). The improvement was significantly greater in group II (P less than 0·05) according to the predefined score. After corticosteroids were discontinued, inflammatory signs recurred in nine patients in group I and in one of group II. During the observation period of 12 months, relapses occurred in eight out of twenty patients in group I and in only one out of twenty in group II. Muscle thickness decreased in nine patients in group II, 6 months after beginning therapy. At this time, the results were not influenced in any of the twenty patients in group I. Microsomal antibodies decreased significantly (P less than 0·001) in the ciclosporin group, whereas no change was seen in the other group. Renal values rose within the normal range in group II. In this group, an infection with Klebsiella pneumoniae occurred in one patient after 4 months of therapy. A rebound phenomenon after stopping ciclosporin has not yet been observed. Thus the drug ciclosporin proved to be effective both in terms of improvement of the acute effect as well in relapse prophylaxis of Graves' ophthalmopathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2362.1986.tb01016.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 202

Metadata

Authors
KAHALY, G., SCHREZENMEIR, J., KRAUSE, U., SCHWEIKERT, B., MEUER, S., MULLER, W., DENNERAUM, R., & BEYER, J.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
1986-10
Volume
16
Issue
5
Pages
415-422
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2023660047
Cited by
202
References
1
FWCI
3.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. https://app.cochat.ai/papers/10.1111/j.1365-2362.1986.tb01016.x
The paper
KAHALY, G., SCHREZENMEIR, J., KRAUSE, U., SCHWEIKERT, B., MEUER, S., MULLER, W., DENNERAUM, R., & BEYER, J. (1986). Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.1986.tb01016.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.